Alnylam Pharmaceuticals filings document the regulatory record for a Nasdaq-listed biopharmaceutical company built around RNA interference therapeutics. Recent Form 8-K reports furnish operating results and financial condition updates tied to product revenues from AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO, while other current reports disclose strategy updates, pipeline goals and clinical-program context.
The filing record also covers governance and capital structure matters, including the definitive proxy statement, executive compensation and equity-award disclosures, common stock registered on Nasdaq, a revolving credit facility and convertible senior note offering materials. These disclosures describe board oversight, compensation plans, financing arrangements, material corporate events and the formal exhibits supporting Alnylam's public-company reporting.
Alnylam Pharmaceuticals is asking stockholders to vote at its virtual 2026 annual meeting on May 20, 2026 at 10:30 a.m. Eastern Time. Holders of record as of March 25, 2026 can participate online and vote.
Stockholders will elect three Class I directors—Stuart Arbuckle, CEO Yvonne L. Greenstreet, M.D., and Elliott Sigal, M.D., Ph.D.—for terms ending in 2029, cast an advisory say‑on‑pay vote on executive compensation, and ratify PricewaterhouseCoopers LLP as independent auditors for 2026.
The proxy highlights Alnylam’s classified board structure, majority voting policy, and a board composed of nine independent and one management director, with a mix of biopharma, financial, governance and scientific expertise. It also details ESG and corporate responsibility initiatives, including patient access programs, climate and data governance work, and a refreshed director compensation mix of cash, stock options and RSUs.
Alnylam Pharmaceuticals Inc: Amendment No. 10 to a Schedule 13G/A filed by The Vanguard Group reports zero shares beneficially owned of Alnylam common stock and 0% ownership as disclosed in the form. The filing includes a statement that Vanguard reorganized certain subsidiaries on January 12, 2026, and those entities will report separately following SEC Release No. 34-39538.
ALNYLAM PHARMACEUTICALS, INC. EVP and Chief R&D officer Pushkal Garg reported open-market sales of 4,713 shares of common stock on March 4–5, 2026, at prices generally in the low-to-mid $320s per share, in multiple transactions.
The filing notes that some shares were automatically sold by the company to cover minimum statutory tax withholding when restricted stock units vested, and that certain transactions were executed under a Rule 10b5-1 trading plan adopted on November 20, 2025. Following these sales, Garg directly held 18,693 common shares, with additional indirect holdings reported through a managed account and a trust, the latter with a disclaimer of beneficial ownership.
Alnylam Pharmaceuticals Chief Executive Officer Yvonne Greenstreet reported automatic tax-related stock sales. On March 4, 2026, she sold a total of 2,933 shares of Alnylam common stock in a series of open-market transactions, at weighted average prices ranging from about $318 to $326 per share.
According to the disclosure, these sales were executed by the company under a mandatory sell-to-cover provision to satisfy minimum statutory tax withholding tied to vesting restricted stock units. After these sales, Greenstreet directly owned 95,695 shares, and also held 407 shares indirectly through a managed account related to the company’s 401(k) matching program.
ALNYLAM PHARMACEUTICALS, INC. executive vice president and chief financial officer Jeffrey V. Poulton reported selling 2,468 shares of common stock on March 4, 2026 in a series of open-market sales. Reported prices for these transactions include $319.03, $320.01, $320.81, $321.82, $323.01, $323.84, $324.88 and $325.67 per share.
According to a footnote, these shares were automatically sold by the company under a mandatory sell-to-cover provision to satisfy minimum statutory tax withholding obligations upon the vesting of restricted stock units. After these sales, Poulton directly owned 62,028 shares and indirectly held 57 shares of ALNY common stock through a managed account.
ALNYLAM PHARMACEUTICALS, INC. executive officer Tanguler Tolga reported automatic sales of common stock tied to equity compensation. On March 4, 2026, a total of 2,309 shares of common stock were sold in multiple open‑market transactions.
According to a footnote, these shares were sold by the company on the reporting person’s behalf under a mandatory sell-to-cover provision to satisfy minimum statutory tax withholding upon vesting of restricted stock units. After these sales, the reporting person directly held 34,297 common shares.
Alnylam Pharmaceuticals CSO & EVP, Head of Research Kevin Joseph Fitzgerald reported open-market sales of company stock. On March 4–5, 2026, he sold a total of 1,291 shares of common stock in multiple transactions at prices generally in the low $320 range.
Footnotes state that some shares were automatically sold by the company under a mandatory sell-to-cover provision to satisfy minimum tax withholding on vested restricted stock units, and that the transactions were made under a Rule 10b5-1(c) trading plan adopted on August 14, 2025. After these sales, Fitzgerald directly owns 20,569 common shares and indirectly holds 537 shares through a managed account associated with the company’s 401(k) matching program.
ALNY reports a Rule 144 notice to sell 658 RSUs slated on 03/03/2026. The filing also lists three reported sales by Kevin Fitzgerald: 01/13/2026 (2290 shares, $848,062.57), 02/17/2026 (2041 shares, $677,531.58), and 03/03/2026 (1652 shares, $528,187.85).